Myeloid Cell Targeting Therapeutics Market by Type of Molecule, Therapeutic Area, Route of Administration and Geography (North America, Europe and Asia Pacific), 2021-2035
Myeloid Cell Targeting Therapeutics Market by Type of Molecule (Small Molecule and Biologics), Therapeutic Area (Oncological Disorders and Rare Disorders), Route of Administration (Intravenous and Oral) and Geography (North America, Europe and Asia Pacific), 2021-2035
Report Link: https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html
The market for therapeutics targeting myeloid cells is currently valued at $0.65 billion in 2022 and is projected to grow at a remarkable CAGR of over 40% during the forecast period.
In 2020, there were over 19 million new cancer cases reported, with approximately 10 million cancer-related deaths, indicating a rapid increase in the global cancer burden. In response to this growing prevalence, researchers have made substantial efforts to explore innovative approaches for the treatment of oncological diseases. Among the various programs that have advanced to clinical stages, myeloid cell targeting therapeutics have emerged as a novel strategy within the realm of cancer immunotherapy.
Myeloid cells encompass a group of cells comprising granulocytes, monocytes, macrophages, mast cells, and dendritic cells, all of which play a crucial role in innate immunity. These cells are found abundantly in the tumor microenvironment and inflamed regions. Tumors recruit and manipulate endogenous myeloid cells, transforming them into tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells, and neutrophils to sustain an immunosuppressive environment. Several research studies have demonstrated that myeloid cells can interact with the immune system to generate an effective anti-tumor immune response. Targeting these cells can help modulate cancer-associated activities, including immune evasion. Therefore, myeloid therapies have garnered significant attention as potential complements to existing treatments, such as immune checkpoint inhibitors, dendritic cell vaccines, oncolytic viruses, and chemoradiation, aiming to enhance therapeutic responses. Moreover, myeloid cell targeting therapies are under investigation for their potential in the treatment of various inflammatory disorders.
At present, numerous medical researchers and industry stakeholders are actively involved in developing therapeutics that target myeloid cells to harness the immune system for treating various solid tumors, leukemias, and even rare conditions like myelodysplastic syndrome and ANCA-associated vasculitis. The substantial data from ongoing studies and completed trials indicate that targeting myeloid cells leads to delayed tumor progression, ultimately improving patient survival rates. This encouraging progress has attracted significant attention from private and public investors, who have collectively invested around USD 4.9 billion in recent years. Fueled by increasing research and development activities, promising clinical data, and financial support from investors, the market for myeloid cell targeting therapeutics is poised to experience substantial growth during the forecast period.
Key Market Segments
Type of Molecule
Report Link: https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html
The market for therapeutics targeting myeloid cells is currently valued at $0.65 billion in 2022 and is projected to grow at a remarkable CAGR of over 40% during the forecast period.
In 2020, there were over 19 million new cancer cases reported, with approximately 10 million cancer-related deaths, indicating a rapid increase in the global cancer burden. In response to this growing prevalence, researchers have made substantial efforts to explore innovative approaches for the treatment of oncological diseases. Among the various programs that have advanced to clinical stages, myeloid cell targeting therapeutics have emerged as a novel strategy within the realm of cancer immunotherapy.
Myeloid cells encompass a group of cells comprising granulocytes, monocytes, macrophages, mast cells, and dendritic cells, all of which play a crucial role in innate immunity. These cells are found abundantly in the tumor microenvironment and inflamed regions. Tumors recruit and manipulate endogenous myeloid cells, transforming them into tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells, and neutrophils to sustain an immunosuppressive environment. Several research studies have demonstrated that myeloid cells can interact with the immune system to generate an effective anti-tumor immune response. Targeting these cells can help modulate cancer-associated activities, including immune evasion. Therefore, myeloid therapies have garnered significant attention as potential complements to existing treatments, such as immune checkpoint inhibitors, dendritic cell vaccines, oncolytic viruses, and chemoradiation, aiming to enhance therapeutic responses. Moreover, myeloid cell targeting therapies are under investigation for their potential in the treatment of various inflammatory disorders.
At present, numerous medical researchers and industry stakeholders are actively involved in developing therapeutics that target myeloid cells to harness the immune system for treating various solid tumors, leukemias, and even rare conditions like myelodysplastic syndrome and ANCA-associated vasculitis. The substantial data from ongoing studies and completed trials indicate that targeting myeloid cells leads to delayed tumor progression, ultimately improving patient survival rates. This encouraging progress has attracted significant attention from private and public investors, who have collectively invested around USD 4.9 billion in recent years. Fueled by increasing research and development activities, promising clinical data, and financial support from investors, the market for myeloid cell targeting therapeutics is poised to experience substantial growth during the forecast period.
Key Market Segments
Type of Molecule
- Small Molecule
- Biologics
- Oncological Disorders
- Rare Disorders
- Intravenous
- Oral
- North America
- Europe
- Asia Pacific
- The report studies the myeloid cell targeting therapeutics market by type of molecule, therapeutic area, route of administration and geography.
- The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
- The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
- The report forecasts the revenue of market segments with respect to major regions.
- An overview of key findings from our research on the myeloid cell targeting therapeutics market, offering insights into its current state and likely evolution in the short, mid, and long term.
- A comprehensive evaluation of the current market landscape for myeloid cell-targeting therapeutics, considering key parameters like development phase (clinical and preclinical), molecule type (small molecules and biologics), target indications, therapeutic areas (oncological disorders, hepatic disorders, autoimmune disorders, inflammatory diseases, respiratory disorders, neurological disorders, renal disorders, rheumatological disorders, immunological disorders, and others), biological targets, administration routes (intravenous, oral, subcutaneous, intra-tumoral, nasal, and others), therapy types (monotherapy and combination therapy), combination drugs, treatment lines, and dosing frequencies. Additionally, it provides information about companies involved in the development of myeloid cell-targeting therapeutics, including their establishment year, company size, and headquarters location.
- Comprehensive profiles of key players engaged in myeloid cell-targeting therapeutics development. Each profile includes a brief company overview, details about their drug candidates, available financial information (if applicable), recent developments, and an informed future outlook.
- In-depth analysis of completed and ongoing clinical trials related to myeloid cell-targeting therapeutics. The analysis considers trial status, registration year, sponsor/collaborator type, study design, and enrolled patient numbers. Additionally, the chapter highlights trends over the years in completed and ongoing trials, patient age groups, participation of industry and non-industry players, and trial locations.
- A thorough review of over 10,000 peer-reviewed scientific articles related to myeloid cell-targeting therapeutics research. Analysis includes parameters such as publication year, emerging research focus, publication type, therapeutic area, and target indication. The chapter also identifies leading journals and authors (based on the number of articles published).
- Detailed examination of academic grants awarded to various research institutes for myeloid cell-targeting therapeutics projects from 2017 to 2021. Parameters considered include grant award year, funding amount, funding institute center type, notable NIH departments, support duration, emerging research areas, grant purposes, grant activity codes, local grant recipients, recipient organization study sections, and grant application types. Additionally, the chapter highlights top recipient organizations based on the number of grants and total funding received, along with prominent program officers.
- Analysis of partnerships established within the myeloid cell-targeting therapeutics market since 2017, encompassing research and development agreements, clinical trial agreements, mergers/acquisitions, product development and commercialization agreements, licensing agreements, asset acquisitions, and product development/manufacturing agreements.
- A comprehensive analysis of investments made in companies focused on myeloid cell-targeting therapeutics since 2017, including grants, seed financing, venture capital financing, IPOs, secondary offerings, other equity investments, post-IPO equity investments, and equity crowdfunding.
- An examination of start-ups/small companies engaged in the development of myeloid cell-targeting therapeutics, considering pipeline strength, pipeline maturity, indication diversity, financial backing, number of investors, partnership activity, and start-up health indexing.
- A case study on companies developing macrophage-based therapeutics, including analyses of development phase, molecule type, target indications, therapeutic areas, establishment year, company size, and headquarters location of the involved companies.
- The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
- Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
- The report provides stakeholders with a pulse on the myeloid cell targeting therapeutics market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
- You will get access to complimentary PPT insights and excel data packs / dynamic dashboards to easily navigate through complex analyses / charts.
- ChemoCentryx
- Daiichi Sankyo
- Gilead Sciences
- Janssen Biotech
- Roche
- Pfizer
- GlaxoSmithKline
- Macrophage Pharma
- Enlivex, Immune-Onc Therapeutics
- Infinity Pharmaceuticals
- AstraZeneca
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Myeloid Cell Line
3.2. Origin, Differentiation and Identification of Myeloid Cells
3.3. Multifaceted Functions of Myeloid Cells
3.4. Receptors Controlling Migration and Activation of Myeloid Cells
3.5. Recruitment of Myeloid Cells in Tumor Microenvironment (TME)
3.6. Role of Myeloid Cells in Tumor Progression and Suppression
3.7. Approaches to Select and Target Myeloid Cells in TME
3.8. Myeloid Cells and Anti-tumor Therapies
3.9. Factors Affecting Therapeutic Efficacy of Myeloid Cell Targeting Therapeutics
3.10. Challenges Associated with Myeloid Cell Targeting
3.11. Future Perspectives
4. MYELOID CELLS TARGETING THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Myeloid Cells Targeting Therapeutics Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Target Indication(s)
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Biological Target(s)
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Combination Drug(s)
4.2.9. Analysis by Line of Treatment
4.2.10. Analysis by Dosing Frequency
4.3. Myeloid Cells Targeting Therapeutics Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Therapeutics
4.3.5. Most Active Players: Analysis by Phase of Development of Drugs
5. MYELOID CELLS TARGETING THERAPEUTICS DEVELOPERS: COMPANY PROFILES
5.1. Companies with Drugs in Advanced Stages of Development
5.1.1. ChemoCentryx
5.1.1.1. Company Overview
5.1.1.2. Financial Information
5.1.1.3. Drug Portfolio
5.1.1.4. Recent Developments and Future Outlook
5.1.2. Daiichi Sankyo
5.1.2.1. Company Overview
5.1.2.2. Financial Information
5.1.2.3. Drug Portfolio
5.1.2.4. Recent Developments and Future Outlook
5.1.3. Gilead Sciences
5.1.3.1. Company Overview
5.1.3.2. Financial Information
5.1.3.3. Drug Portfolio
5.1.3.4. Recent Developments and Future Outlook
5.2. Companies with Multiple Therapeutic Development Programs
5.2.1. Janssen Biotech
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Drug Portfolio
5.2.1.4. Recent Developments and Future Outlook
5.2.2. Roche
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Drug Portfolio
5.2.2.4. Recent Developments and Future Outlook
5.2.3. Pfizer
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Drug Portfolio
5.2.3.4. Recent Developments and Future Outlook
5.2.4. GlaxoSmithKline
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Drug Portfolio
5.2.4.4. Recent Developments and Future Outlook
5.2.5. Macrophage Pharma
5.2.5.1. Company Overview
5.2.5.2. Financial Information
5.2.5.3. Drug Portfolio
5.2.5.4. Recent Developments and Future Outlook
5.2.6. Enlivex
5.2.6.1. Company Overview
5.2.6.2. Financial Information
5.2.6.3. Drug Portfolio
5.2.6.4. Recent Developments and Future Outlook
5.2.7. Immune-Onc Therapeutics
5.2.7.1. Company Overview
5.2.7.2. Financial Information
5.2.7.3. Drug Portfolio
5.2.7.4. Recent Developments and Future Outlook
5.2.8. Infinity Pharmaceuticals
5.2.8.1. Company Overview
5.2.8.2. Financial Information
5.2.8.3. Drug Portfolio
5.2.8.4. Recent Developments and Future Outlook
5.2.9. AstraZeneca
5.2.9.1. Company Overview
5.2.9.2. Financial Information
5.2.9.3. Drug Portfolio
5.2.9.4. Recent Developments and Future Outlook
6. CLINICAL TRIALS ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Myeloid Cells Targeting Therapeutics: List of Clinical Trials
6.2.1. Analysis by Trial Status
6.2.2. Analysis by Trial Registration Year
6.2.3. Analysis by Type of Sponsor / Collaborator
6.2.4. Analysis by Registration Year and Type of Study
6.2.5. Analysis by Study Design
6.2.6. Analysis by Patient Enrollment
6.2.7. Year-wise Trend of Completed and Recruiting Trials
6.2.8. Analysis by Age Category
6.2.9. Analysis by Phase of Development and Trial Status
6.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.2.12. Analysis by Trial Location
6.2.13. Analysis by Trial Status and Geography
7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Myeloid Cells Targeting Therapeutics: List of Publications
7.3. Analysis by Year of Publication
7.4. Analysis by Emerging Focus Area
7.5. Analysis by Type of Publication
7.6. Analysis by Therapeutic Area
7.7. Analysis by Target Indication
7.8. Top Journals: Analysis by Number of Publications
7.9. Top Authors: Analysis by Number of Publications
8. ACADEMIC GRANTS ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Myeloid Cells Targeting Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded
8.5. Analysis by Type of Funding Institute Center
8.6. Popular NIH Departments: Analysis by Number of Grants
8.7. Analysis by Support Period
8.8. Analysis by Emerging Focus Area
8.9. Analysis by Purpose of Grants
8.10. Analysis by Grant Activity Code
8.11. Analysis by Local Recipients
8.12. Analysis by Type of Recipient Organization
8.13. Popular Recipient Organization: Analysis by Number of Grants
8.14. Popular Recipient Organization: Analysis by Amount Awarded
8.15. Prominent Program Officers: Analysis by Number of Grants
8.16. Analysis by Study Section
8.17. Analysis by Type of Grant Application
8.18. Analysis by Funding Institute Center and Support Year
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Analysis Methodology and Key Parameters
9.2. Partnership Models
9.3. Myeloid Cells Targeting Therapeutics: List of Partnerships and Collaborations
9.4. Analysis by Year of Partnership
9.5. Analysis by Type of Partnership
9.6. Analysis by Year and Type of Partnership
9.7. Analysis by Type of Myeloid Cells Targeted
9.8. Analysis by Type of Molecule
9.9. Analysis by Therapeutic Area
9.10. Analysis by Type of Partner
9.11. Most Active Players: Analysis by Number of Partnerships
9.12. Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Type of Funding
10.3. Myeloid Cells Targeting Therapeutics: List of Funding Instances
10.4. Analysis by Year of Funding
10.5. Analysis by Amount Invested
10.6. Analysis by Type of Funding
10.7. Analysis by Type of Funding and Amount Invested
10.8. Analysis by Year, Type of Funding and Amount Invested
10.9. Analysis by Type of Myeloid Cells Targeted
10.10. Analysis by Therapeutic Area
10.11. Analysis by Target Indication
10.12. Most Active Players: Analysis by Number of Funding Instances
10.13. Most Active Players: Analysis by Amount Invested
10.14. Key Investors: Analysis by Number of Funding Instances
10.15. Analysis by Geographical Regions
10.16. Analysis by Year and Type of Funding
10.17. Summary of Funding Instances
11. START-UP HEALTH INDEXING
11.1. Analysis Methodology and Key Parameters
11.2. Analysis by Pipeline Strength
11.3. Analysis by Pipeline Maturity
11.4. Analysis by Indication Diversity
11.5. Analysis by Financial Support
11.6. Analysis by Number of Investors
11.7. Analysis by Partnership Activity
11.8. Start-up Health Indexing: Roots Analysis Perspective
12. CASE STUDY: MACROPHAGE-BASED THERAPEUTICS DEVELOPERS
12.1 Overview and Key Parameters
12.2. Macrophage-based Therapeutics: List of Therapies
12.2.1. Analysis by Phase of Development
12.2.2. Analysis by Type of Molecule
12.2.3. Analysis by Target Indication(s)
12.2.4. Analysis by Therapeutic Area
12.3. Macrophage -based Therapeutic Developers
12.3.1. Analysis by Year of Establishment
12.3.2. Analysis by Company Size
12.3.3. Analysis by Location of Headquarters
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Forecast Methodology and Key Assumptions
13.1. Global Myeloid Cells Targeting Therapeutics Market, 2021-2035
13.2. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Type of Molecule
13.2.1. Myeloid Cells Targeting Therapeutics Market for Small Molecules, 2021-2030
13.2.2. Myeloid Cells Targeting Therapeutics Market for Biologics, 2021-2030
13.3. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Therapeutic Area
13.3.1. Myeloid Cells Targeting Therapeutics Market for Oncological Disorders, 2021-2030
13.3.1. Myeloid Cells Targeting Therapeutics Market for Oncological Disorders, 2021-2030
13.3.2. Myeloid Cells Targeting Therapeutics Market for Rare Disorders, 2021-2030
13.4. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Route of Administration
13.4.1. Myeloid Cells Targeting Therapeutics Market for Intravenous Route, 2021-2030
13.4.2. Myeloid Cells Targeting Therapeutics Market for Oral Route, 2021-2030
13.5. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Geography
13.5.1. Myeloid Cells Targeting Therapeutics in North America, 2021-2030
13.5.2. Myeloid Cells Targeting Therapeutics in Europe, 2021-2030
13.5.3. Myeloid Cells Targeting Therapeutics in Asia Pacific, 2021-2030
14. EXECUTIVE INSIGHTS
14.1. Montis Bioscience
14.1.1. Company Snapshot
14.1.2. Interview Transcript: Rene Hoet (Chief Scientific Officer)
14.2. Carisma Therapeutics
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Tom Wilton (Chief Business Officer)
15. APPENDIX 1: LIST OF FIGURES AND TABLES
16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Myeloid Cell Line
3.2. Origin, Differentiation and Identification of Myeloid Cells
3.3. Multifaceted Functions of Myeloid Cells
3.4. Receptors Controlling Migration and Activation of Myeloid Cells
3.5. Recruitment of Myeloid Cells in Tumor Microenvironment (TME)
3.6. Role of Myeloid Cells in Tumor Progression and Suppression
3.7. Approaches to Select and Target Myeloid Cells in TME
3.8. Myeloid Cells and Anti-tumor Therapies
3.9. Factors Affecting Therapeutic Efficacy of Myeloid Cell Targeting Therapeutics
3.10. Challenges Associated with Myeloid Cell Targeting
3.11. Future Perspectives
4. MYELOID CELLS TARGETING THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Myeloid Cells Targeting Therapeutics Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Target Indication(s)
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Biological Target(s)
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Combination Drug(s)
4.2.9. Analysis by Line of Treatment
4.2.10. Analysis by Dosing Frequency
4.3. Myeloid Cells Targeting Therapeutics Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Therapeutics
4.3.5. Most Active Players: Analysis by Phase of Development of Drugs
5. MYELOID CELLS TARGETING THERAPEUTICS DEVELOPERS: COMPANY PROFILES
5.1. Companies with Drugs in Advanced Stages of Development
5.1.1. ChemoCentryx
5.1.1.1. Company Overview
5.1.1.2. Financial Information
5.1.1.3. Drug Portfolio
5.1.1.4. Recent Developments and Future Outlook
5.1.2. Daiichi Sankyo
5.1.2.1. Company Overview
5.1.2.2. Financial Information
5.1.2.3. Drug Portfolio
5.1.2.4. Recent Developments and Future Outlook
5.1.3. Gilead Sciences
5.1.3.1. Company Overview
5.1.3.2. Financial Information
5.1.3.3. Drug Portfolio
5.1.3.4. Recent Developments and Future Outlook
5.2. Companies with Multiple Therapeutic Development Programs
5.2.1. Janssen Biotech
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Drug Portfolio
5.2.1.4. Recent Developments and Future Outlook
5.2.2. Roche
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Drug Portfolio
5.2.2.4. Recent Developments and Future Outlook
5.2.3. Pfizer
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Drug Portfolio
5.2.3.4. Recent Developments and Future Outlook
5.2.4. GlaxoSmithKline
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Drug Portfolio
5.2.4.4. Recent Developments and Future Outlook
5.2.5. Macrophage Pharma
5.2.5.1. Company Overview
5.2.5.2. Financial Information
5.2.5.3. Drug Portfolio
5.2.5.4. Recent Developments and Future Outlook
5.2.6. Enlivex
5.2.6.1. Company Overview
5.2.6.2. Financial Information
5.2.6.3. Drug Portfolio
5.2.6.4. Recent Developments and Future Outlook
5.2.7. Immune-Onc Therapeutics
5.2.7.1. Company Overview
5.2.7.2. Financial Information
5.2.7.3. Drug Portfolio
5.2.7.4. Recent Developments and Future Outlook
5.2.8. Infinity Pharmaceuticals
5.2.8.1. Company Overview
5.2.8.2. Financial Information
5.2.8.3. Drug Portfolio
5.2.8.4. Recent Developments and Future Outlook
5.2.9. AstraZeneca
5.2.9.1. Company Overview
5.2.9.2. Financial Information
5.2.9.3. Drug Portfolio
5.2.9.4. Recent Developments and Future Outlook
6. CLINICAL TRIALS ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Myeloid Cells Targeting Therapeutics: List of Clinical Trials
6.2.1. Analysis by Trial Status
6.2.2. Analysis by Trial Registration Year
6.2.3. Analysis by Type of Sponsor / Collaborator
6.2.4. Analysis by Registration Year and Type of Study
6.2.5. Analysis by Study Design
6.2.6. Analysis by Patient Enrollment
6.2.7. Year-wise Trend of Completed and Recruiting Trials
6.2.8. Analysis by Age Category
6.2.9. Analysis by Phase of Development and Trial Status
6.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.2.12. Analysis by Trial Location
6.2.13. Analysis by Trial Status and Geography
7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Myeloid Cells Targeting Therapeutics: List of Publications
7.3. Analysis by Year of Publication
7.4. Analysis by Emerging Focus Area
7.5. Analysis by Type of Publication
7.6. Analysis by Therapeutic Area
7.7. Analysis by Target Indication
7.8. Top Journals: Analysis by Number of Publications
7.9. Top Authors: Analysis by Number of Publications
8. ACADEMIC GRANTS ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Myeloid Cells Targeting Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded
8.5. Analysis by Type of Funding Institute Center
8.6. Popular NIH Departments: Analysis by Number of Grants
8.7. Analysis by Support Period
8.8. Analysis by Emerging Focus Area
8.9. Analysis by Purpose of Grants
8.10. Analysis by Grant Activity Code
8.11. Analysis by Local Recipients
8.12. Analysis by Type of Recipient Organization
8.13. Popular Recipient Organization: Analysis by Number of Grants
8.14. Popular Recipient Organization: Analysis by Amount Awarded
8.15. Prominent Program Officers: Analysis by Number of Grants
8.16. Analysis by Study Section
8.17. Analysis by Type of Grant Application
8.18. Analysis by Funding Institute Center and Support Year
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Analysis Methodology and Key Parameters
9.2. Partnership Models
9.3. Myeloid Cells Targeting Therapeutics: List of Partnerships and Collaborations
9.4. Analysis by Year of Partnership
9.5. Analysis by Type of Partnership
9.6. Analysis by Year and Type of Partnership
9.7. Analysis by Type of Myeloid Cells Targeted
9.8. Analysis by Type of Molecule
9.9. Analysis by Therapeutic Area
9.10. Analysis by Type of Partner
9.11. Most Active Players: Analysis by Number of Partnerships
9.12. Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Type of Funding
10.3. Myeloid Cells Targeting Therapeutics: List of Funding Instances
10.4. Analysis by Year of Funding
10.5. Analysis by Amount Invested
10.6. Analysis by Type of Funding
10.7. Analysis by Type of Funding and Amount Invested
10.8. Analysis by Year, Type of Funding and Amount Invested
10.9. Analysis by Type of Myeloid Cells Targeted
10.10. Analysis by Therapeutic Area
10.11. Analysis by Target Indication
10.12. Most Active Players: Analysis by Number of Funding Instances
10.13. Most Active Players: Analysis by Amount Invested
10.14. Key Investors: Analysis by Number of Funding Instances
10.15. Analysis by Geographical Regions
10.16. Analysis by Year and Type of Funding
10.17. Summary of Funding Instances
11. START-UP HEALTH INDEXING
11.1. Analysis Methodology and Key Parameters
11.2. Analysis by Pipeline Strength
11.3. Analysis by Pipeline Maturity
11.4. Analysis by Indication Diversity
11.5. Analysis by Financial Support
11.6. Analysis by Number of Investors
11.7. Analysis by Partnership Activity
11.8. Start-up Health Indexing: Roots Analysis Perspective
12. CASE STUDY: MACROPHAGE-BASED THERAPEUTICS DEVELOPERS
12.1 Overview and Key Parameters
12.2. Macrophage-based Therapeutics: List of Therapies
12.2.1. Analysis by Phase of Development
12.2.2. Analysis by Type of Molecule
12.2.3. Analysis by Target Indication(s)
12.2.4. Analysis by Therapeutic Area
12.3. Macrophage -based Therapeutic Developers
12.3.1. Analysis by Year of Establishment
12.3.2. Analysis by Company Size
12.3.3. Analysis by Location of Headquarters
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Forecast Methodology and Key Assumptions
13.1. Global Myeloid Cells Targeting Therapeutics Market, 2021-2035
13.2. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Type of Molecule
13.2.1. Myeloid Cells Targeting Therapeutics Market for Small Molecules, 2021-2030
13.2.2. Myeloid Cells Targeting Therapeutics Market for Biologics, 2021-2030
13.3. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Therapeutic Area
13.3.1. Myeloid Cells Targeting Therapeutics Market for Oncological Disorders, 2021-2030
13.3.1. Myeloid Cells Targeting Therapeutics Market for Oncological Disorders, 2021-2030
13.3.2. Myeloid Cells Targeting Therapeutics Market for Rare Disorders, 2021-2030
13.4. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Route of Administration
13.4.1. Myeloid Cells Targeting Therapeutics Market for Intravenous Route, 2021-2030
13.4.2. Myeloid Cells Targeting Therapeutics Market for Oral Route, 2021-2030
13.5. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Geography
13.5.1. Myeloid Cells Targeting Therapeutics in North America, 2021-2030
13.5.2. Myeloid Cells Targeting Therapeutics in Europe, 2021-2030
13.5.3. Myeloid Cells Targeting Therapeutics in Asia Pacific, 2021-2030
14. EXECUTIVE INSIGHTS
14.1. Montis Bioscience
14.1.1. Company Snapshot
14.1.2. Interview Transcript: Rene Hoet (Chief Scientific Officer)
14.2. Carisma Therapeutics
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Tom Wilton (Chief Business Officer)
15. APPENDIX 1: LIST OF FIGURES AND TABLES
16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
